Tests a new method to predict colorectal cancer return after treatment
Studies a test that aims to predict whether colon or rectal cancer returns in adults.
Plain-language title generated from the registry record
Registry title: Stage II/III Colorectal Cancer Recurrence
Key facts
- Where
- Barcelona and Madrid, SpainSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III or high-risk stage II colorectal cancer who had surgery and then chemotherapy, and are now free of cancer.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- High-risk stage II or stage III colorectal cancer (TNM classification, 8th edition).
- Earlier treatment
- Stage-specific surgery meant to remove all of the cancer, followed by chemotherapy after surgery. Standard diagnosis and staging as per local guidelines.
Main reasons for not taking part
- No written informed consent
- Cancer came back in the first 6 months after finishing chemotherapy
- Hereditary colorectal cancer syndromes found by genetic testing
- Inflammatory bowel disease
Read by machine on 12 November 2026.
Where in Spain
- Barcelona UniversityBarcelona, SpainContact: Francesc Balaguer, MD, PhDTaking people
- La Paz University HospitalMadrid, SpainContact: Marta MendiolaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- City of Hope Medical Center
- Trial code
- NCT06314958
- Record updated
- 7 July 2026
- Original description
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.Read full original descriptionShow less
Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment
This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.
Inclusion: Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition); Received standard diagnostic, staging, and therapeutic procedures as per local guidelines; Received stage-specific curative-intent resection followed by adjuvant chemotherapy; Confirmed cancer-free survivorship confirmed at the time of study inclusion.
Exclusion: Development of recurrence in the first 6 months following adjuvant chemotherapy completion; Hereditary colorectal cancer syndromes (identified through genetic testing); Inflammatory bowel diseases; Lack of written informed consent.